Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immutep Limited (NASDAQ: IMMP).

Full DD Report for IMMP

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMMP)

Midday Gainers / Losers (09/06/2018)
Gainers: ARWR +45% . WSCI +34% . CVM +28% . ABAC +24% . CLDR +23% . SDPI +22% . NBEV +17% . SUPV +17% . AVAV +17% . IMMP +15% . More news on: Arrowhead Pharmaceuticals, WSI Industries Inc., Cel-Sci Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 06 2018 13:03
Progress Towards Clinical Development of IMP761 - a LAG-3 Agonist Antibody
SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”),  a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announces that it will commence c...
Source: GlobeNewswire
Date: September, 03 2018 08:00
Midday Gainers / Losers (08/31/2018)
Gainers:  AOBC +37% . PDEX +23% . TLYS +19% . INNT +19% . GGAL +19% . BMA +19% . TPIV +18% . SUPV +17% . EDN +16% . LULU +16% . More news on: American Outdoor Brands Corporation, Pro-Dex, Inc., Tilly's, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 31 2018 12:42
Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
SYDNEY, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has ...
Source: GlobeNewswire
Date: August, 21 2018 04:44
Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
SYDNEY, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced today that it has been invited t...
Source: GlobeNewswire
Date: August, 16 2018 08:00
TACTI-mel Patient Recruitment Complete and Operational Update
Patient recruitment completed for Part B of ongoing TACTI-mel Phase I clinical trial Progress on Immutep’s TACTI-002 and AIPAC GSK nominates ulcerative colitis as its lead indication for IMP731 ( GSK2831781 ) Novartis commences new Phase II trial for IMP701 (LAG525) in ...
Source: GlobeNewswire
Date: August, 07 2018 08:00
Your Daily Pharma Scoop: Puma Progresses, Kala In Phase 3, Teva Fails
Stocks in the News: PBYI, KALA Puma Bio's Nerlynx marketing application in Canada under review Puma Biotechnology's ( PBYI ) New Drug Submission (‘NDS) for NERLYNX ( neratinib ) for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer is...
Source: SeekingAlpha
Date: August, 02 2018 06:35
3 Things In Biotech, August 1: Eisai Has A Big Portent
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Eisai and Merck break through in a tough malignancy Company: Eisai ( ESALY ) and Merck ...
Source: SeekingAlpha
Date: August, 01 2018 08:00
Immutep on go to start mid-stage study of eftilagimod alpha
The FDA has signed off on Immutep Limited's ( IMMP -6.1% ) IND for IMP321 (eftilagimod alpha), a LAG-3Ig fusion protein. The company plans to launch a Phase 2 clinical trial, TACTI-002, evaluating the combination of IMP321 and Merck's KEYTRUDA (pembrolizumab) in patients with non-small c...
Source: SeekingAlpha
Date: July, 31 2018 09:49
Immutep's LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval From U.S. FDA
On schedule to initiate the TACTI-002 Phase II clinical study in 2H 2018 SYDNEY, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce the approval of its Investigational New Dr...
Source: GlobeNewswire
Date: July, 30 2018 21:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-083.083.023.082.84226,713
2018-05-172.192.132.22242.1346,305

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-09-2016,97749,87634.0384Cover
2018-09-1923,19993,95924.6906Cover
2018-09-1813,55144,56930.4045Cover
2018-09-1714,79042,30734.9588Cover
2018-09-1415,00922,14167.7883Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMP.


About Immutep Limited (NASDAQ: IMMP)

Logo for Immutep Limited (NASDAQ: IMMP)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: IMMP)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: IMMP)

      Daily Technical Chart for (NASDAQ: IMMP)


      Stay tuned for daily updates and more on (NASDAQ: IMMP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: IMMP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMMP and does not buy, sell, or trade any shares of IMMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/